within Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IA08_Technetium99mtcEtarfolat;

model Technetium99mtcEtarfolat
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 5e-08,
    adminDuration = 600,
    adminMass = 0.01 / 1000000,
    adminCount = 1,
    Vd = 0.005,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Technetium99mtcEtarfolatide</td></tr><tr><td>ATC code:</td><td>V09IA08</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.01</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.18</td><td>L/hr</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Technetium (99mTc) etarfolatide is a radiopharmaceutical agent consisting of a technetium-99m labeled folate receptor-targeting ligand. It is used for single photon emission computed tomography (SPECT) imaging to identify folate receptor positive tumors, primarily in ovarian and other cancers. The drug is not currently FDA-approved and was primarily used in clinical trials.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult cancer patients based on typical radiopharmaceutical and SPECT imaging protocols; no published clinical pharmacokinetic models available.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V09IA08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Technetium99mtcEtarfolat;
